Mise en place d’un outil d’aide à la détection des interactions physico-chimiques en Y des médicaments injectables : analyse rétrospective des prescriptions dans un service d’hématologie

Le Pharmacien Hospitalier et Clinicien - Tập 54 - Trang 348-355 - 2019
G. Sicard1, G. Venton2, L. Farnault2, R. Costello2, R. Fanciullino1,3, S. Gensollen3
1SMARTc, CRCM, UMR Inserm 1068, CNRS UMR 7258, Aix Marseille université U105, faculté de pharmacie, 27, boulevard Jean-Moulin - CS 30064, 13385 Marseille, France
2Service d’hématologie, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France
3Pharmacie, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France

Tài liệu tham khảo

Kanji, 2013, Inappropriate medication administration practices in Canadian adult ICUs: a multicenter, cross-sectional observational study, Ann Pharmacother, 47, 637, 10.1345/aph.1R414

Tissot, 1999, Medication errors at the administration stage in an intensive care unit, Intensive Care Med, 25, 353, 10.1007/s001340050857

Taxis, 2003, Causes of intravenous medication errors: an ethnographic study, Qual Saf Health Care, 12, 343, 10.1136/qhc.12.5.343

Haroche, 2011, Perfusion: des montages trop complexes ?, Oxymag, 24, 28

Benlabed, 2018, Analysis of particulate exposure during continuous drug infusion in critically ill adult patients: a preliminary proof-of-concept in vitro study, Intensive Care Med Exp, 6, 38, 10.1186/s40635-018-0205-2

D’Arcy, 1983, Drug interactions with medical plastics, Drug Intell Clin Pharm, 17, 726, 10.1177/106002808301701005

Florence, 1998, Physicochemical Drug Interactions and Incompatibilities, 449

Newton, 1978, Physicochemical determinants of incompatibility and instability in injectable drug solutions and admixtures, Am J Hosp Pharm, 35, 1213

Raverdy, 2013, Stability and compatibility of vancomycin for administration by continuous infusion, J Antimicrob Chemother, 68, 1179, 10.1093/jac/dks510

Korth-Bradley, 1995, Incompatibility of amiodarone hydrochloride and sodium bicarbonate injections, Am J Health-Syst Pharm, 52, 2340, 10.1093/ajhp/52.20.2340

Trissel, 1997, Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration, Am J Health Syst Pharm, 54, 1287, 10.1093/ajhp/54.11.1287

Steadman, 2010, Evaluation of a Potential Clinical Interaction between Ceftriaxone and Calcium, Antimicrob Agents Chemother, 54, 1534, 10.1128/AAC.01111-09

Agence nationale de sécurité du médicament et des produits de santé. Ceftriaxone et incompatibilités physico-chimiques, particulièrement avec les solutions contenant des sels de calcium - Modifications des Résumés des Caractéristiques du Produit ; décembre 2006. [En ligne]. Disponible sur: https://ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Ceftriaxone-et-incompatibilites-physico-chimiques-particulierement-avec-les-solutions-contenant-des-sels-de-calcium-Modifications-des-Resumes-des-Caracteristiques-du-Produit.[Consulté le: 15-avr-2019].

Cavatur, 2002, Crystallization behavior of mannitol in frozen aqueous solutions, Pharm Res, 19, 894, 10.1023/A:1016177404647

Agence européenne des médicaments. Résumé des caractéristiques du produit Advagraf. Disponible sur: https://www.ema.europa.eu/en/documents/product-information/advagraf-epar-product-information_fr.pdf.(consulté le 20 juin 2019).

Létalon, 2017, Interactions contenant/contenu, Médicament Info Service, 2

Vermeire, 1999, Stability and compatibility of morphine, Int J Pharm, 187, 17, 10.1016/S0378-5173(99)00181-7

Chaix, 1950, L’étude cinétique de l’oxydation de l’adrénaline en solution tampon-phosphate, Biochim Biophys Acta, 4, 471, 10.1016/0006-3002(50)90053-9

Ahmad, 2016, Photostability and photostabilization of drugs and drug products, Int J Photoenergy, 10.1155/2016/8135608

University of Illinois at Chicago College of Pharmacy, 2014, Light-Sensitive Injectable Prescription Drugs, Hosp Pharm, 49, 136, 10.1310/hpj4902-136

Lemercier, 2000, Pharmacocinétique et pharmacodynamie du valaciclovir et du famciclovir, Méd Mal Infect, 30, 455, 10.1016/S0399-077X(00)80005-0

Kaestli, 2006, Administration de médicaments par voie parentérale et incompatibilités physico-chimiques, CAPP-Info, 1

Cervenka, 1992, Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration, Hosp Pharm, 27, 957

Shoghi, 2013, Solubility–pH profiles of some acidic, basic and amphoteric drugs, Eur J Pharm Sci, 48, 291, 10.1016/j.ejps.2012.10.028

Factors That Affect Reaction Rates. Chemistry LibreTexts, 24-nov-2013. [En ligne]. Disponible sur: https://chem.libretexts.org/Bookshelves/Physical_and_Theoretical_Chemistry_Textbook _Maps/Supplemental_Modules_(Physical_and_Theoretical_Chemistry)/Kinetics/Reactio n_Rates/Factors_That_Affect_Reaction_Rates. [Consulté le: 18-avr-2019]

Trissel, 1998, Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration, Hosp Pharm, 33, 284

Closset, 2017, Physical stability of highly concentrated injectable drugs solutions used in intensive care units, Ann Pharm Fr, 75, 185, 10.1016/j.pharma.2016.12.004

Murphy, 2017, Cytarabine and daunorubicin for the treatment of acute myeloid leukemia, Expert Opin Pharmacother, 18, 1765, 10.1080/14656566.2017.1391216

Mokart, 2008, Patient d’oncohématologie neutropénique fébrile admis en réanimation, recommandations actuelles et attitude pratique, Réanimation, 17, 213, 10.1016/j.reaurg.2008.01.010

Le Bourgeois, 2018, Allogreffe: nouveautés et perspectives, Rev Francoph Lab, 52

Allwood, 1998, Compatibility and stability of additives in parenteral nutrition admixtures, Nutrition, 14, 697, 10.1016/S0899-9007(98)00063-X

Bouchoud, 2013, Nutrition parentérale et médicaments: modalités d’une administration concomitante, Nutr Clin Metab, 27, 263, 10.1016/j.nupar.2013.08.001

Bouchoud, 2013, Compatibility of intravenous medications with parenteral nutrition: in vitro evaluation, J Parenter Enteral Nutr, 37, 416, 10.1177/0148607112464239

Robinson, 2009, Y-site compatibility of medications with parenteral nutrition, J Pediatr Pharmacol Ther, 14, 48

Trissel, 1999, Compatibility of medications with 3-in-1 parenteral nutrition admixtures, J Parenter Enteral Nutr, 23, 67, 10.1177/014860719902300267

Staven, 2016, Development and evaluation of a test program for Y-site compatibility testing of total parenteral nutrition and intravenous drugs, Nutr J, 15, 29, 10.1186/s12937-016-0149-x

Handbook on Injectable Drugs, 20th Edition. AHFS Drug Information, 2018

Gray, 2011, Injectable Drugs Guide, Pharmaceutical Press

Benlabed, 2019, Clinical implications of intravenous drug incompatibilities in critically ill patients, Anaesth Crit Care Pain Med, 38, 173, 10.1016/j.accpm.2018.04.003

Pharmacie des Hôpitaux universitaires de Genève. Compatibilité des médicaments injectables administrés en Y. Disponible sur: https://pharmacie.hug-ge.ch/infomedic/utilismedic/HUG_CompatAdm_DCI.pdf (consulté le 20 juin 2019).

Trissel, 1994, Compatibility of filgrastim with selected drugs during simulated Y-site administration, Am J Hosp Pharm, 51, 1907

IV Drug Compatibility Chart of selected meds.pdf | Epinephrine | Drugs, Scribd. [En ligne]. Disponible sur: https://www.scribd.com/document/317197877/IV-Drug-Compatibility-Chart-of-selected-meds-pdf. [Consulté le 16-avr-2019]

Perez, 2015, In vitro analysis of overall particulate contamination exposure during multidrug IV therapy: impact of infusion sets, Pediatr Blood Cancer, 62, 1042, 10.1002/pbc.25442

Anderson, 2014, Physical and chemical compatibility of injectable acetaminophen during simulated y-site administration, Hosp Pharm, 49, 42, 10.1310/hpj4901-42

Forman, 1987, Visual compatibility of acyclovir sodium with commonly used intravenous drugs simulated Y-site injection, Am J Hosp Pharm, 44, 1408

Staven, 2017, Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents, J Pharm Pharmacol, 69, 448, 10.1111/jphp.12647

Péré, 2004, Compatibilité du pantoprazole injectable lors d’administration en Y, Pharmactuel, 37, 193

Jack, 2012, In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial, Intensive Care Med, 38, 1008, 10.1007/s00134-012-2539-7

Berkane, 2016, Évaluation d’un programme de réduction des incompatibilités physico-chimiques en réanimation médicale au CHU de Grenoble, Th D Pharm

Thông tin
Thông tin xuất bản

Le Pharmacien Hospitalier et Clinicien

Tập 54

348-355

Thông tin tác giả